Q1 EPS Estimates for Nuvation Bio Lowered by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Nuvation Bio in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.17) per share for the quarter, down from their prior estimate of ($0.15). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio's Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.71) EPS.

NUVB has been the subject of a number of other research reports. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price objective (up previously from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Wedbush reiterated an "outperform" rating and issued a $5.00 price target on shares of Nuvation Bio in a research note on Monday, March 3rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $8.00.

Nuvation Bio Stock Performance

Shares of NUVB stock opened at $2.31 on Wednesday. The stock has a market capitalization of $775.79 million, a P/E ratio of -1.06 and a beta of 1.47. The company has a 50 day moving average price of $2.39 and a 200 day moving average price of $2.57. Nuvation Bio has a fifty-two week low of $1.67 and a fifty-two week high of $4.16.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Nuvation Bio by 5.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 103,939 shares of the company's stock worth $276,000 after buying an additional 5,693 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Nuvation Bio by 0.5% during the 4th quarter. Two Sigma Investments LP now owns 1,151,256 shares of the company's stock worth $3,062,000 after buying an additional 5,925 shares during the last quarter. Zacks Investment Management lifted its position in shares of Nuvation Bio by 21.5% during the 3rd quarter. Zacks Investment Management now owns 36,125 shares of the company's stock worth $83,000 after buying an additional 6,394 shares during the last quarter. LPL Financial LLC lifted its position in shares of Nuvation Bio by 27.0% during the 4th quarter. LPL Financial LLC now owns 31,348 shares of the company's stock worth $83,000 after buying an additional 6,673 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Nuvation Bio by 2.3% during the 4th quarter. Invesco Ltd. now owns 330,388 shares of the company's stock worth $879,000 after buying an additional 7,344 shares during the last quarter. Hedge funds and other institutional investors own 61.67% of the company's stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.